Economics of stratified medicine in rheumatoid arthritis

Sean Gavan, Mark Harrison, Cynthia Paola Iglesias Urrutia, Anne Barton, Andrea Manca, Katherine Payne

Research output: Contribution to journalArticlepeer-review

Abstract

Clinically relevant examples of stratified medicine are available for patients with rheumatoid arthritis (RA). The aim of this study was to understand the current economic evidence for stratified medicine in RA. Two systematic reviews were conducted to identify: (1) all economic evaluations of stratified treatments for rheumatoid arthritis, or those which have used a subgroup analysis, and (2) all stated preference studies of treatments for rheumatoid arthritis. Ten economic evaluations of stratified treatments for RA, 38 economic evaluations including with a subgroup analysis and eight stated preference studies were identified. There was some evidence to support that stratified approaches to treating a patient with RA may be cost-effective. However, there remain key gaps in the economic evidence base needed to support the introduction of stratified medicine in RA into healthcare systems and considerable uncertainty about how proposed stratified approaches will impact future patient preferences, outcomes and costs when used in routine practice.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalCurrent Rheumatology Reports
Volume16
Issue number12
DOIs
Publication statusPublished - 4 Nov 2014

Keywords

  • Antirheumatic Agents
  • Arthritis, Rheumatoid
  • Cost-Benefit Analysis
  • Health Care Costs
  • Humans
  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Review

Cite this